Ferguson Wellman Capital Management Inc. Has $102.76 Million Stock Holdings in Amgen Inc. $AMGN

Ferguson Wellman Capital Management Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 2.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 313,938 shares of the medical research company’s stock after buying an additional 6,372 shares during the period. Amgen comprises approximately 1.6% of Ferguson Wellman Capital Management Inc.’s holdings, making the stock its 18th largest holding. Ferguson Wellman Capital Management Inc.’s holdings in Amgen were worth $102,755,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Sequoia Financial Advisors LLC lifted its holdings in Amgen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after buying an additional 3,619 shares during the period. Davis Capital Management acquired a new stake in Amgen during the 3rd quarter worth $1,841,000. D.A. Davidson & CO. raised its position in shares of Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after acquiring an additional 6,222 shares during the last quarter. Global Wealth Management Investment Advisory Inc. lifted its stake in shares of Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after purchasing an additional 4,699 shares during the period. Finally, Jones Financial Companies Lllp lifted its stake in shares of Amgen by 18.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock valued at $10,888,000 after purchasing an additional 6,115 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of Amgen stock opened at $353.93 on Thursday. The company has a market capitalization of $190.79 billion, a PE ratio of 24.87, a PEG ratio of 3.46 and a beta of 0.45. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock’s fifty day simple moving average is $361.76 and its 200 day simple moving average is $329.23.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the previous year, the firm earned $5.31 earnings per share. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. Amgen’s payout ratio is currently 70.84%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on AMGN shares. Deutsche Bank Aktiengesellschaft lifted their price objective on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. Royal Bank Of Canada raised their target price on Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Leerink Partners restated a “market perform” rating and set a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Finally, Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.